Figure 7.
Interference in the formation of the 14-3-3ζ–c-Src–integrin-β3 complex in thrombosis without affecting hemostasis. (A) Oral administration of THO (100 mg/kg) alleviated 10% of the FeCl3-induced occlusive carotid artery thrombosis in mice. (B) Oral administration of THO (100 mg/kg) reduced the mouse tail thrombus induced by 40 mg/kg carrageenan. (C) Tail transection bleeding times of mice orally receiving THO (100 mg/kg) or clopidogrel (100 mg/kg) at 3, 6, and 12 hours after administration. (D) The number of RBCs in peritoneal lavage after a calibrated injury of the liver in mice treated with THO (100 mg/kg) or clopidogrel (10 mg/kg) at 3, 6, and 12 hours after administration. (E-F) Effect of oral administration of THO (100 mg/kg) or clopidogrel (100 mg/kg) on bleeding in the mouse brain. Photographs (E) and relative quantification (F) of the areas of brain bleeding. (G-H) In vitro effects of 100 μM THO, myr-KF7, and their relative controls on clot retraction of human platelet-rich plasma in the presence of 0.03 U/mL thrombin. Data are expressed as means ± SD (n = 3). *P < .05; **P < .01.

Interference in the formation of the 14-3-3ζ–c-Src–integrin-β3 complex in thrombosis without affecting hemostasis. (A) Oral administration of THO (100 mg/kg) alleviated 10% of the FeCl3-induced occlusive carotid artery thrombosis in mice. (B) Oral administration of THO (100 mg/kg) reduced the mouse tail thrombus induced by 40 mg/kg carrageenan. (C) Tail transection bleeding times of mice orally receiving THO (100 mg/kg) or clopidogrel (100 mg/kg) at 3, 6, and 12 hours after administration. (D) The number of RBCs in peritoneal lavage after a calibrated injury of the liver in mice treated with THO (100 mg/kg) or clopidogrel (10 mg/kg) at 3, 6, and 12 hours after administration. (E-F) Effect of oral administration of THO (100 mg/kg) or clopidogrel (100 mg/kg) on bleeding in the mouse brain. Photographs (E) and relative quantification (F) of the areas of brain bleeding. (G-H) In vitro effects of 100 μM THO, myr-KF7, and their relative controls on clot retraction of human platelet-rich plasma in the presence of 0.03 U/mL thrombin. Data are expressed as means ± SD (n = 3). *P < .05; **P < .01.

Close Modal

or Create an Account

Close Modal
Close Modal